Mutant clones drive chronic human autoimmune diseases

(mis à jour)

Le 19 mai 2025 à 14h30 Séminaire

Professor Chris Goodnow FAA FRS is Executive Director of the Garvan Institute of Medical Research, holds The Bill and Patricia Ritchie Foundation Chair as Head of the Immunogenomics Laboratory at Garvan, and is Professor and Director of the Cellular Genomics Futures Institute at UNSW Sydney. Chris is internationally recognised for discovering and establishing the concept of sequential tolerance checkpoints to prevent the immune system attacking “self” while fighting off “foreign” infections, laying the scientific foundation for the recent success of checkpoint inhibitor drugs to activate immune destruction of “self” cancer cells. He pioneered the use of mammalian genome sequencing to reveal how the body’s phenotype results from its’ genotype – “phenomics”. Most recently his team have used single cell genomics to discover that “rogue" immune cells bypass tolerance checkpoints to cause autoimmune disease through mutation pathways that also cause lymphoma and leukemia.Chris’ many awards include the AAI Pharmingen Award, Gottschalk Medal, Health Minister’s Prize, Centenary Medal, Ramaciotti Medal, GSK Award for Research Excellence, William E. Paul Award, Fellow of the Australian Academy of Science, Fellow of the Royal Society, and Member of the US National Academy of Sciences.
In this seminar, Prof. Christopher Goodnow will describe their soon-to-be-published work using single cell multi-omics to identify B or T cell clones with molecular aberrations shared with lymphoma that are responsible for treatment-refractory vasculitis, neuropathy and celiac disease.